Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Asenapine

Abstract

In August 2009, asenapine (Saphris; Schering–Plough) was approved by the US FDA for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. van Os, J. & Kapur, S. Schizophrenia. Lancet 374, 635–645 (2009).

    Article  CAS  Google Scholar 

  2. Belmaker, R. H. Bipolar disorder. N. Engl. J. Med. 351, 476–486 (2004).

    Article  CAS  Google Scholar 

  3. Miyamoto, S. et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79–104 (2005).

    Article  CAS  Google Scholar 

  4. Meltzer, H. Y., Matsubara, S. & Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 25, 238–246 (1989).

    Google Scholar 

  5. Broekkamp, C. L. et al. Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors. Arzneimittelforschung 40, 544–549 (1990).

    CAS  PubMed  Google Scholar 

  6. De Boer, T. et al. Neurochemical studies with the potential antipsychotic compound trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrolidine maleate. Arzneimittelforschung 40, 550–554 (1990).

    CAS  PubMed  Google Scholar 

  7. Franberg, O. et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology 196, 417–429 (2008).

    Article  CAS  Google Scholar 

  8. Food and Drug Administration. FDA labelling information. FDA website [online] (2009).

  9. Shahid, M. et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol. 23, 65–73 (2009).

    Article  CAS  Google Scholar 

  10. Potkin, S. G., Cohen, M. & Panagides, J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J. Clin. Psychiatry 68, 1492–1500 (2007).

    Article  CAS  Google Scholar 

  11. Meltzer, H. Y. Treatment-resistant schizophrenia — the role of clozapine. Curr. Med. Res. Opin. 14, 1–20 (1997).

    Article  CAS  Google Scholar 

  12. Meltzer, H. Y. et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 60, 82–91 (2003)

    Article  CAS  Google Scholar 

  13. Tiihonen, J. et al. Mortality in schizophrenia: an 11-year follow-up study of the total Finnish population (FIN11 Study). Lancet 374, 620–627 (2009).

    Article  Google Scholar 

  14. Leucht, S. et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 14, 429–447 (2009).

    Article  CAS  Google Scholar 

  15. Volpi, S. et al. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J. Clin. Psychiatry 70, 801–809 (2009).

    Article  CAS  Google Scholar 

  16. Lieberman, J. A. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209–1223 (2005).

    Article  CAS  Google Scholar 

  17. Tiihonen, J. et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333, 224–227 (2006).

    Article  Google Scholar 

  18. IMS MIDAS (IMS Health, 2009).

  19. Arnold, C. et al. Credit Suisse Equity Research Report (Credit Suisse Security, 3 Feb 2009).

    Google Scholar 

  20. Schott, C. et al. JP Morgan North America Equity Research Report (JP Morgan & Chase, 3 Feb 2009).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

H.Y.M. is a grantee of and a consultant for Lilly, Janssen, Pfizer, Minster, Abbott, Acadia, Dainippon Sumitomo, Azur, Otsuka, Bristol–Myers Squibb and Organon. He is also a consultant for Schering–Plough, Merck, AstraZeneca, Novartis, Biovail and Boehringer Ingelheim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meltzer, H., Dritselis, A., Yasothan, U. et al. Asenapine. Nat Rev Drug Discov 8, 843–844 (2009). https://doi.org/10.1038/nrd3027

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3027

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing